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High Blood Ammonia Levels Associated with 
Long-term Valproic Acids Therapy in Epileptic Children
I Gusti Lanang Sidiartha, I Gusti Ngurah Made Suwarba, Dyah Kanya Wati, Ida Bagus Subanada
Child Health Department, Faculty of Medicine, Udayana University/Sanglah General Hospital, Bali, Indonesia
Background: Valproic acid is an effective drug for controlling seizure in children with epilepsy and it is usually used for 
treatment as long as two years or more. Blood ammonia level often increased in epileptic children who were treated 
with long-term valproic acid. The study was conducted to determine the relationship between blood ammonia level with 
valproic acid therapy in epileptic children.
Materials and Methods: This is an observational study with cross-sectional approach. The subjects were 64 children 
with epilepsy, average age of 6.2 years old. Subjects were 33 boys and 31 girls. Blood ammonia level was examined using 
enzymatic glutamate dehydrogenase. Subjects were divided into 2 therapeutic groups based on the duration, doses and 
combination therapy of valproic acid. Subjects were recruited from Pediatric Neurology Clinic, Sanglah General Hospital, 
Bali, Indonesia, from May to December 2017. Comparison of blood ammonia level between groups were analyzed using an 
Independent t-test with significances if the p<0.05. 
Results:  A significant difference of blood ammonia level was found between subjects who were treated with valproic acid 
less than 2 years and more than 2 years (45.7±16.4 mmol/L vs. 70.9±43.6 mmol/L; p=0.032). However, significant difference 
was not found between the groups according to the doses and combination therapy (p=0.450 and p=0.647, respectively).
Conclusion: Blood ammonia level was significantly higher in epileptic children who used long-term valproic acid, hence it 
was recommended to check the blood ammonia level routinely.
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Introduction
As an anti-epileptic drug (AED), valproic acid (VPA) is 
widely used in treatment of seizure in children. However, 
although VPA is highly effective in controlling seizure in 
children, it also has several adverse effects such as fatigue, 
gastrointestinal disturbances, weight gain, muscle tremors, 
hair loss, thrombocytopenia, and an increase in hepatic 
enzymes.1,2 Other than that, VPA also increases blood 
ammonia concentrations (hyperammonemia) in adults3-7 
and children8-15. The actual increases in blood ammonia 
concentrations depend on the dose of VPA4,8 and the use of 
long-term therapy with VPA5. 
 Several studies have reported the relationship 
between blood ammonia concentrations and VPA therapy. 
The increase of blood ammonia concentrations is depend 
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on the dose and duration of VPA and combination therapy 
with phenytoin, phenobarbital or topiramate, as well as 
with female gender.4,8 The mechanism of hyperammonemia 
directly inhibits carbamoyl phosphate synthetase (CPS), an 
enzyme that cause imbalances between the synthesis and 
degradation of ammonia in the liver and indirectly inhibits 
the fatty acid beta-oxidation pathway.4 Ammonia is toxic, 
especially to the central nervous system. An increased level 
of ammonia in the blood is linked with encephalopathy and 
a worsening of the prognosis for epilepsy. 
 The study investigated the relationship between 
blood ammonia concentrations with valproic acid therapy, 
including duration, doses, and combination therapy. Those 
variables adjusted on some specific factors as confounding 
variables such as age, gender, body mass index, and duration 
of epilepsy. 
Materials and methods
A cross-sectional study was carried out with 64 sample of 
children with epilepsy who were treated with VPA or VPA 
and other AEDs for more than 3 months. Children were 
excluded if they were suffering from metabolic diseases, 
were receiving therapeutic drugs including salicylate, and/
or undergoing chemotherapy for more than a week, and 
having high levels of glutamic oxaloacetic transaminase 
(GOT)/glutamic pyruvic transaminase (GPT) and blood 
urea nitrogen (BUN)/serum creatinine (SC). The GOT/GPT 
and BUN/SC levels were considered high if it was >4 times 
of range normal, while the normal GOT level=11.0-33.0 
U/L; normal GPT level=11.0-50.0 U/L; normal BUN 
level=8.0-23.0 mg/dL; normal SC level=0.70-1.20 mg/dL. 
 The study was conducted at the Pediatric Neurologic 
Clinic, Sanglah General Hospital, Denpasar, Bali, Indonesia, 
over an 8-months period from May to December 2017. 
The Ethical Committee of the Medical Faculty, Udayana 
University/Sanglah General Hospital, granted ethical 
approval with No. 2017/UN.14.2/KEP/2017. 
 Data were collected through anamnesis, physical 
examination, and medical record, and blood specimen were 
drawn to check the concentration of GOT/GPT, BUN/SC, 
and blood ammonia levels. Blood ammonia examination 
uses enzymatic glutamate dehydrogenase (Cobas Integra, 
Roche, Basel, Switzerland). After the data were collected, 
the subjects were divided into 2 groups based on the 
duration they had been receiving VPA therapy (≥2 years 
and <2 years), VPA doses (≥30 mg/kg/day and <30 mg/
kg/day), and type of VPA therapy (either it was single drug 
and multiple drugs or VPA only and VPA + other AEDs), 
respectively. Subject’s blood ammonia concentrations were 
then compared between the groups. 
 The sample size calculation was according to formula 
with a=0.05 power=80% and clinical difference of blood 
ammonia level 10 μmol/L. The achieved minimal sample 
size was 64.5. Normality of the numerical data was tested 
using Kolmogorov-Smirnov and presented as a mean and 
standard deviation (SD). The differences between the groups 
were tested using an Independent-t test, and multivariate 
analysis using ANCOVA7. The data was considered 
statistically significant if the p<0.05.
Results
There were 74 children with epilepsy treated with VPA during 
the period of this study. Sixty-four subjects were included in 
this study after fulfilled the exclusion and inclusion criteria. 
Of these 64, 33 were male (51.6%) and 31 female (48.4%) 
with a mean age of 6.2 years old. Subjects mean duration of 
an epilepsy diagnosis was 3.1 years and their mean duration 
of treatment with VPA was 2.4 years. Table 1 illustratesthe 
breakdown of subjects overall characteristics.
Characteristic Mean (SD)
Age (years old) 6.2 (3.3)
Body weight (kg) 25.1 (14.3)
Body height (cm) 115.7 (21.0)
Body mass index (kg/m2) 17.0 (3.8)
Duration of epilepsy (years) 3.1 (2.5)
Duration of VPA (years) 2.4 (1.9)
VPA doses (mg/kg/day) 24.7 (3.6)
Blood ammonia levels (µmol/L) 53.8 (30.2)
Characteristic n (%)
Gender
     Male 33 (51.6)
     Female 31 (48.4)
AED therapy
     Single 10 (15.6)
     Multiple 54 (84.4)
Table 1. Characteristics of subjects (n=64).
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Table 2. Bivariate analysis of blood ammonia levels between groups.




     ≥2 years 70.9 (43.6) 25.2 2.3;48.1 0.032
     <2 years 45.7 (16.4)
VPA doses
     ≥30 mg/kg 63.3 (18.9) 11.4 -19.1;41.9 0.450
     <30 mg/kg 51.9 (31.9)
Combined therapy
     Yes 66.1 (29.8) 14.8 -67.6;97.2 0.647
     No 51.3 (3.6)
*Independent t-test.
Variable Type III Sum of Squares F p -value
Duration of epilepsy 17.979 0.136 0.719
Body mass index 345.868 2.607 0.130
Age 6.876 0.052 0.823
Gender 6279.656 47.33 0.001
VPA duration 675.093 5.088 0.042
VPA doses 312.300 2.354 0.149
Combined therapy 258.944 1.952 0.186
Table 3. Analysis of covariance of subjects' blood ammonia.
 A blood ammonia concentration of more than 60 
mmol/L is classified as hyperammonemia, in this study, 22 
subjects (34.4%) exhibited hyperammonemia. The mean 
differences in blood ammonia concentrations between the 
groups according to the duration of VPA therapy, doses 
of VPA, and combination therapy was analyzed using an 
Independent t-test and is presented in Table 2.
 Multivariate analysis using ANCOVA was done to 
adjust several confounding variable, such as age and gender. 
The result of the ANCOVA analysis was still significant 
for the duration of VPA therapy (p=0.042), but not for  the 
VPA doses (p=0.149) and combined therapy (p=0.186) as 
presented in Table 3. 
Discussion
This study found the blood ammonia concentrations in 
children with epilepsy were 53.8 mmol/L. However, other 
studies reported different results. They reported that blood 
ammonia concentrations in children with epilepsy were 
46.5 mmol/L and 50.9 mmol/L, respectively.8,9 Their results 
were lower than those found in the present study. It may be 
related with the aged of the subjects. 
 In the present study, the subject’s mean aged were 
6.2 years while in the other two studies cited above, they 
were 7.1 years and 9.2 years, respectively.8,9 Thus, the lower 
mean aged in the subjects of the present study means that 
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they were likely to exhibit higher concentrations of blood 
ammonia.9 
 The blood ammonia concentrations of the subjects 
who receiving VPA therapy for two years or more were 
significantly higher than those of subjects who receiving 
VPA therapy for less than two years. The blood ammonia 
concentrations of each group were 70.9 mmol/L and 45.7 
mmol/L respectively with a mean difference of 25.2 mmol/L. 
Studies on adults with epilepsy reported that the duration 
of VPA therapy had no significant associations with 
higher blood ammonia concentration.4 Blood ammonia 
concentration more closely correlated with VPA doses and 
blood VPA concentration.
 In the present study, subjects receiving doses of VPA 
were divided into two groups: (1) those on 30 mg/kg/day, 
and (2) those on less than 30 mg/kg/day. The first group 
tends to have higher blood ammonia concentrations than 
the second (63.3 mmol/L vs. 51.9 mmol/L), respectively, 
although this was not statistically significant. Other studies 
reported that blood ammonia concentrations had a positive 
correlation with the dose of VPA. Higher doses of VPA 
will result in higher blood ammonia concentrations.8,9 The 
blood ammonia concentrations of children with epilepsy 
who received VPA therapy with doses of <10 mg/kg, 10-
20 mg/kg, 20-30 mg/kg and >30 mg/kg were 46.8 mg/dL, 
60.4 mg/dL 85.7 mg/dL and 92.6 mg/dL, respectively.8 The 
dose of VPA apparently appeared to be correlated with 
blood ammonia concentration in children with epilepsy was 
30.4 mg/kg or more.9 Studies in adults also reported that 
VPA dose was an independent risk factor of blood ammonia 
concentration.4 
 Another variable that was analyzed in this study 
was the combination therapy (multi-drug approaches) 
using VPA in combination with other AEDs. Subjects who 
received multi-drug treatments (VPA and others AEDs) 
showed higher levels of blood ammonia compared with 
those received single drug treatment (VPA only) at 66.1 
mmol/L and 51.3 mmol/L, respectively, although this was 
not statistically significant. However, the other study found 
a significantly higher of blood ammonia concentrations in 
subjects who received combination therapy of VPA and other 
AEDs, particularly phenytoin and phenobarbital.8 Studies in 
adults also reported that combination therapy, particularly 
liver enzyme-inducing AEDs such as carbamazepine, 
phenytoin and phenobarbital, resulted in significantly higher 
concentration of blood ammonia.4 
 One interesting result of the present study was the 
interaction between the duration of VPA therapy, multi-
drug therapy, and male gender on the basis of multivariate 
analysis. Male subjects who received multi-drug therapy for 
2 years or more showed significantly higher blood ammonia 
concentrations than their counterparts. This means that 
routine blood ammonia monitoring should be carried out 
with all epilepsy children who have been receiving VPA for 
2 years or more, especially in males who have been received 
combination therapies consisting of VPA and other AEDs. 
  Another key result was the prevalence of 
hyperammonemia detected. A diagnostic criterion for 
hyperammonemia varies between studies. One study 
used a cut off 40 mmol/L and another 60 mmol/L The 
study using a cut of 60 mmol/L and found the prevalence 
of hyperammonemia was 34.4% while other studies have 
reported that the prevalence of hyperammonemia varied 
between 31.7% and 50%.8,9
 Epileptic children with VPA at levels exceeded 
30.4 mg/kg/day tend to show a higher prevalence of 
hyperammonemia. Ammonia, produced as a byproduct 
of protein metabolism, should be converted to urea in the 
liver, via the urea-cycle pathway and then excreted in the 
kidneys. Metabolites of VPA such as valpronyl-coenzyme A 
propionate and 2-n-propyl-4-pentanoic acid (4-en-VPA) can 
inhibit the activity of enzymes in the urea-cycle pathway 
causing hyperammonemia. Ammonia is toxic, especially to 
the central nervous system, and therefore, increased blood 
ammonia concentrations in children with epilepsy should be 
prevented to improve the prognosis of epilepsy. 
Conclusion
Increased blood ammonia concentrations in children with 
epilepsy who received VPA therapy was prevalent. Routine 
blood ammonia monitoring is needed, especially in children 
with epilepsy who have been receiving VPA therapy for 
more than 2 years. Particular attention should be given in 
male children with epilepsy who have been receiving multi-
drug therapy (VPA combined with other AEDs).
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